Comparative Study of Gavage and Intraperitoneal Administration of Gamma-oryzanol in Alleviation/attenuation in a Rat Animal Model of Renal Ischemia/reperfusion-induced Injury
Overview
Authors
Affiliations
Objectives: Ischemia/reperfusion (I/R) is the leading cause of acute kidney injury. This study aimed to elucidate the reno-protective effect of gamma-oryzanol (GO) by comparing gavage and intraperitoneal (IP) administration methods on renal I/R injury in a rat model.
Materials And Methods: Rats were divided into four groups including (group 1) sham, (group 2) I/R-control, (group 3) I/R+GO gavage-treated, and (group 4) I/R+ GO IP-treated. A single dose of GO was administrated to groups 3 and 4 (100 mg/kg body weight), 60 min before induction of I/R. After anesthesia, I/R was created by 45 min of ischemia, followed by 6 hr of reperfusion. Then, blood and tissue samples were subjected to evaluation of renal function, anti-oxidant capacity, inflammation, apoptotic proteins, and IKB/NF-kB pathway.
Results: The two GO administration methods showed improvement of renal function along with attenuation of histological abnormalities. An increase in antioxidant capacity along with a decrease in pro-inflammatory markers, decline in the expression levels of BAX, Bax/Bcl-2, and caspase-3, and up-regulation of Bcl-2 expression were recorded. Moreover, a significant decrease in NF-Kb, p-IKBα, and MMP-2/9 with an increase in IKBα levels were also observed. Overall, in a comparative evaluation between the two gavage and IP administration methods, we did not find any differences in all examined parameters, except IL-6 which had a better result via gavage.
Conclusion: A single dose of GO administration has a reno-protective effect against renal I/R injury. Gavage and IP administration exhibit similar efficiency in alleviation of I/R injury.
Shi Y, Min X, Li Y, Guo L, Cai Z, Li D Cytotechnology. 2024; 77(1):5.
PMID: 39575323 PMC: 11579276. DOI: 10.1007/s10616-024-00668-5.
Saberi S, Najafipour H, Rajizadeh M, Etminan A, Jafari E, Iranpour M BMC Nephrol. 2024; 25(1):373.
PMID: 39438873 PMC: 11515705. DOI: 10.1186/s12882-024-03824-3.
Tian Y, Guo J, Mao L, Chen Z, Zhang X, Li Y Stem Cell Res Ther. 2024; 15(1):347.
PMID: 39380054 PMC: 11463110. DOI: 10.1186/s13287-024-03969-w.
Farahzadi R, Fathi E, Vandghanooni S, Valipour B Regen Ther. 2024; 26:646-653.
PMID: 39281104 PMC: 11401101. DOI: 10.1016/j.reth.2024.08.008.
Proteasome and PARP1 dual-target inhibitor for multiple myeloma: Fluzoparib.
Deng K, Li Q, Lu L, Wang L, Cheng Z, Wang S Biochem Biophys Rep. 2024; 39:101781.
PMID: 39071914 PMC: 11279668. DOI: 10.1016/j.bbrep.2024.101781.